Skip Navigation

ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Frank Narjes

Frank Narjes

Frank has more than 20 years’ experience as a medicinal chemist working on multiple small molecule programs across all phases of drug discovery. He is currently Senior Principal Scientist and acting head of the New Modalities group in the Innovative Medicines Unit of AstraZeneca in Sweden, specialising in Respiratory, Inflammation and Autoimmunity targets.

Prior to joining AstraZeneca, he has worked for Merck, Sharp & Dohme focussing on treatments against Hepatitis C virus infection. Frank studied chemistry at the University of Hamburg, followed by postdoctoral studies in the group of Professor Larry Overman at UC Irvine.